Medable Introduces Long-Term Follow-Up Model for Cell & Gene Therapy (CGT) Trials to Reduce Costs and Improve Patient Access
New digital-first solution enables patient engagement and retention while maintaining scientific rigor throughout 15-year CGT trials
PALO ALTO, Calif., May 28, 2025--(BUSINESS WIRE)--Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials. Medable's platform reduces the burden on patients and sites involved in complex CGT trials and enhances scientific integrity with sustainable data capture across the FDA-required 15-year follow-up period for certain CGTs, including those using genome-editing techniques like CRISPR-Cas9. This extended monitoring period is essential for tracking delayed adverse events, understanding the durability of the therapy, and ensuring the long-term impact on patients – but can add significant hardships.
CGTs offer transformative potential yet they also require prolonged safety monitoring, often spanning 15 years post-treatment. Traditional models for LTFU impose logistical and financial challenges on participants, contributing to lower participation and high attrition rates over time. According to a 2024 survey conducted by the Emily Whitehead Foundation and Catalyst Healthcare Consulting, 20% of CAR T-cell therapy patients stop participating in long-term follow-up altogether, with 80% of that group ceasing participation at or after five years post-treatment. Distance to sites, lack of awareness about local follow-up options, and burdensome travel are frequently cited as key barriers.
"Long-term follow-up is essential to ensure the durability and safety of advanced therapies, but the current system isn't working for patients or sponsors," said Dr. Pamela Tenaerts, Chief Medical Officer at Medable. "With our new LTFU model, we're reimagining how post-treatment data is captured - putting patients at the center while ensuring scientific and regulatory rigor."
Medable's digital-first LTFU offering includes:
Remote and Hybrid Patient Interaction: Patients can engage in follow-up through flexible virtual, in-person, or blended formats that meet their individual needs and life circumstances.
Seamless Transition from Parent Trials: Integrated workflows and data continuity ensure a frictionless handoff from interventional studies to long-term observational follow-up.
Patient-First Data Capture and Adherence Monitoring: Leveraging mobile technology, patient reported questionnaires and local healthcare providers to track key endpoints and ensure consistent participation over time.
Personalized Patient Communication: Ongoing engagement through tailored content, reminders, and support tools to build trust and maintain long-term connection.
By embracing a digital, patient-centric approach, Medable's model addresses key gaps in traditional LTFU execution – improving retention, increasing diversity, and reducing the long-term cost burden for both sponsors and sites.
Learn more about Medable's new digital-based LTFU model at American Society of Clinical Oncology's (ASCO) 2025 Annual Meeting (May 30-June 3) in Chicago at Medable Booth #10105.
About Medable
Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable's platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250528631099/en/
Contacts
Media Contact: Lisa Barbadora, Barbadora INK for Medable+1 (610) 420-3413lbarbadora@barbadoraink.com / media@medable.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
KOHL'S INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Kohl's Corporation's Directors and Officers for Breach of Fiduciary Duties
NEW YORK--(BUSINESS WIRE)-- Scott+Scott Attorneys at Law LLP ('Scott+Scott'), an international securities and consumer rights litigation firm, is investigating whether the leadership of Kohl's Corporation ('Kohl's') (NYSE: KSS), breached their fiduciary duties to Kohl's and its shareholders. Scott+Scott is investigating whether members of the Kohl's board of directors or senior management failed to manage Kohl's in an acceptable manner, in breach of their fiduciary duties to Kohl's, and whether Kohl's and its shareholders have suffered damages as a result. On May 1, 2025, Kohl's announced it had fired its CEO for funneling contracts with Kohl's to his romantic partner for above their fair market value. What You Can Do – If you own shares of Kohl's, you may have legal claims against directors and officers of Kohl's. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@ About Us Scott+Scott is an international law firm known for its expertise in representing corporate clients, institutional investors, businesses, and individuals harmed by anticompetitive conduct or other forms of wrongdoings, including securities law and shareholder violations. With more than 100 attorneys in nine offices in the United States, as well as three offices in Europe, our advocacy has resulted in significant monetary settlements on behalf of our clients, along with other forms of relief. Our highly experienced attorneys have been recognized for being among the top financial lawyers in 2024 by Lawdragon, WWL: Commercial Litigation 2024, and Legal 500 in Antitrust Civil Litigation, and have received top Chambers 2024 rankings. In addition, we have been recognized by the American Antitrust Institute for the successful litigation of high-stakes anticompetitive claims in the United States. To learn more about Scott+Scott, our attorneys, or complex case resolution, please visit Attorney Advertising
Yahoo
28 minutes ago
- Yahoo
Important Notice ( Fee Waiver) to the shareholders of Xtrackers II
LONDON, May 30, 2025--(BUSINESS WIRE)-- Xtrackers II Investment Company with Variable Capital Registered office: 49, avenue J.F. Kennedy, L-1855 Luxembourg, R.C.S. Luxembourg B-119.899 (the "Company") Important Notice to Shareholders of Xtrackers II Global Government Bond UCITS ETF (3C-USD Hedged Share Class, ISIN: LU0641006456) (the "Sub-Fund") 30 May 2025 The board of directors of the Company (the "Board of Directors") hereby informs the shareholders of the Sub-Fund (the "Shareholders") about certain temporary reductions in the Management Company Fee (the "Changes"), as described below. DWS Investment S.A., acting in its role as a management company, has agreed to waive part of the Management Company Fee for Share Class 3C-USD Hedged (ISIN: LU0641006456) of the Sub-Fund (the "Share Class") from "up to 0.15% per annum" to "up to 0.05% per annum" for the period from 1 June 2025 until 30 November 2026 inclusive (the "Waiver Period"). The Fixed Fee will remain unchanged at "up to 0.10% per annum" during the Waiver Period. As a result, the All-in Fee of the Sub-Fund will be reduced to "up to 0.15% per annum" during the Waiver Period. For the avoidance of doubt, the Management Company Fee for the Share Class will return to the usual charge of "up to 0.15% per annum" from 1 December 2026, inclusive. As a result, the All-in fee will return to the usual charge of "up to 0.25% per annum" from 1 December 2026. Period 1 June 2025 to 30 November 2026 (Waiver Period) From 1 December 2026 Management Company Fee Fixed Fee All-in Fee Management Company Fee Fixed Fee All-in Fee Xtrackers II Global Government Bond UCITS ETF / 3C-USD Hedged Up to 0.05% per annum Up to 0.10% per annum Up to 0.15% per annum Up to 0.15% per annum Up to 0.10% per annum Up to 0.25% per annum This notice is for information purposes only. Shareholders are not required to take any action. For the avoidance of doubt, due to the temporary character of the Changes, neither the key investor information document of the Sub-Fund nor the Product Annex of the Sub-Fund will be amended. Capitalised terms used herein shall have the meaning ascribed to them in the most recent version of the prospectus of the Company (the "Prospectus") and the Product Annex of the Sub-Fund unless the context otherwise requires. General Information Shareholders who have any queries or to whom any of the above is not clear should seek advice from their stockbroker, bank manager, legal advisor, accountant or other independent financial advisor. Shareholders should also consult their own professional advisors as to the specific tax implications under the laws of the countries of their nationality, residence, domicile or incorporation. Further information in relation to the changes may be obtained from the legal entities mentioned under Contact Information below, the offices of foreign representatives or by sending an email to Xtrackers@ This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Further information in relation to the UK sustainability labelling and disclosure requirements can be found on the UK FCA's website. Neither the contents of the Company's website nor the contents of any other website accessible from hyperlinks on the Company's website is incorporated into, or forms part of, this announcement. Xtrackers II The Board of Directors Contact Information Xtrackers II 49, avenue J.F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg DWS Investment S.A. 2, boulevard Konrad Adenauer, L-1115 Luxembourg, Grand Duchy of Luxembourg View source version on Contacts Xtrackers II
Yahoo
31 minutes ago
- Yahoo
SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contamination at the original manufacturing facility, was removed once new drug batches were produced at a separate location. With trial sites now reactivated, patient enrollment has resumed, reaching about 25% of its 220-participant goal. A pharmacist technician sorting pills in a drug pharmacy. The MARIO trial explores Brexafemme's use as an oral follow-up treatment to IV echinocandins for invasive candidiasis, a life-threatening fungal infection. SCYNEXIS, Inc. (NASDAQ:SCYX) received a $10 million milestone payment from GSK after the first new patient was dosed, though disagreements over further payments and trial duties have sparked tension between the two partners. Previously recalled in 2023 due to contamination risks, Brexafemme had FDA approval for treating VVC. While its commercial progress has faced setbacks, projected global revenue could reach $139 million by 2031 if development succeeds. While we acknowledge the potential of SCYX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SCYX and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
